

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 860 170 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
22.03.2000 Bulletin 2000/12

(51) Int Cl.7: **A61K 49/00**, A61K 9/20,
A61K 31/17, A61K 51/12

(21) Application number: **97934768.9**

(86) International application number:
PCT/JP97/02809

(22) Date of filing: **12.08.1997**

(87) International publication number:
WO 98/06442 (19.02.1998 Gazette 1998/07)

(54) TABLETS BASED ON ISOTOPE-LABELED UREA

TABLETTEN AUF BASIS VON ISOTOPENMARKIERTEM HARNSTOFF
COMPRIMES A BASE D'UREE MARQUEE D'ISOTOPES

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

(74) Representative: **VOSSIUS & PARTNER**
Slebertstrasse 4
81675 München (DE)

(30) Priority: **13.08.1996 JP 21335096**

(56) References cited:
WO-A-96/14091

(43) Date of publication of application:
26.08.1998 Bulletin 1998/35

(73) Proprietor: **KYOWA HAKKO KOGYO CO., LTD.**
Chiyoda-ku, Tokyo 100 (JP)

(72) Inventors:
• **HAYAKAWA, Eiji**
Shizuoka 410-11 (JP)
• **MIURA, Shigemitsu**
Shizuoka 410-11 (JP)
• **ITO, Kunio**
Shizuoka 411 (JP)
• **SAKATO, Kuniaki**
Kanagawa 243-02 (JP)

- **MARSHALL B J ET AL:** "A MICRODOSE, CAPSULE-BASED, 14C-UREA BREATH TEST FOR H.PYLORI" GASTROENTEROLOGY, vol. 100, no. 5, May 1991, page A11B XP000199432
- **PEURA D A ET AL:** "MICRODOSE C-UREA BREATH TEST OFFERS DIAGNOSIS OF HELICOBACTER PYLORI IN 10 MINUTES" AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 91, no. 2, February 1996, pages 233-238, XP000199376
- Edited by **SADAO IGUCHI**, "Comprehensive Technology for the System of Developing New Pharmaceutical Preparations - Bases and Additives (In Japanese)" (1985), R & D PLANNING, p. 410-411, 417-419, 424-438.

EP 0 860 170 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**Technical Field**

5 [0001] The present invention relates to a tablet containing isotope-labeled urea for diagnosing the infection with urease-generating bacteria, particularly Helicobacter pylori.

Background Art

10 [0002] Because Helicobacter pylori has strong urease-producing activity, urea labeled with ^{13}C or ^{14}C is used for diagnosing stomach infected with Helicobacter pylori. Urea labeled with ^{13}C or ^{14}C is prepared as powder, particularly freeze-dried powder, containing urea alone, for oral administration in aqueous solution. The urea labeled with ^{13}C or ^{14}C is degraded by the urease produced by Helicobacter pylori in stomach into carbon dioxide gas labeled with ^{13}C or ^{14}C , which is then released into expired air. By measuring the concentration of the carbon dioxide labeled with ^{13}C or ^{14}C , therefore, the presence or absence of Helicobacter pylori infection can be diagnosed. When the powder is orally
 15 given in aqueous solution, the urea labeled with ^{13}C or ^{14}C is degraded with urease derived from oral bacterial flora, which causes difficulty in diagnosing correctly Helicobacter pylori infection.

[0003] As urea formulations for diagnosing Helicobacter pylori infection, a capsule of ^{14}C -urea [The American Journal of Gastroenterology, 91, 233 (1996)] and a substantially water-soluble composition in solid, containing urea labeled
 20 with an isotope (WO96/14091), have been known.

[0004] However, urea has strong cohesion potency and therefore sticks to tableting machines and the like during the tableting process, which results in poor industrial productivity. Tablets containing urea have so poor hardness that it is difficult to produce high-quality tablets of urea.

Disclosure of Invention

[0005] The present inventors have found that an urea tablet with practical disintegration time and sufficient hardness can be produced by mixing urea with one or several additives among various additives of inorganic compounds and then formulating the mixture into tablet, thereby preventing the stickiness due to the cohesion potency of urea.

30 [0006] The present invention relates to a tablet containing isotope-labeled urea and an inorganic compound, which may further contain an organic compound or a disintegrant.

[0007] Urea with no label is generally composed of carbon atoms of a mass number of 12, oxygen atoms of a mass number of 16, nitrogen atoms of a mass number of 14 and hydrogen atoms of a mass number of 1. The term "isotope-labeled urea" in the present invention means urea labeled with an isotope of at least one of carbon atom, oxygen atom,
 35 nitrogen atom and hydrogen atom, the isotope having a different mass number from the aforementioned mass number of the corresponding atom or a mixture of urea labeled with the isotope and urea with no label. The urea labeled includes preferably urea labeled with ^{13}C , ^{14}C or ^{18}O , and more preferably ^{13}C or ^{14}C . In the present invention, for example, urea labeled with ^{13}C is represented as ^{13}C -urea.

[0008] The inorganic compound includes, for example, inorganic compounds containing silica such as silicic acid anhydride, silicic acid, and silicate; inorganic compounds containing calcium; and inorganic compounds containing aluminium. The silicic acid includes, for example, ortho-silicic acid, meta-silicic acid, meso-disilicic acid, meso-trisilicic acid and meso-tetrasilicic acid. The silicate includes, for example, metal salts of silicic acid. The metal forming silicate includes, for example, aluminum, zinc, potassium, calcium and sodium. The inorganic compounds containing calcium include for example calcium salts. Specific examples include, for example, calcium carbonate, calcium hydrogen phosphate, calcium hydroxide, calcium chloride, calcium sulfate, and calcium nitrate. The inorganic compounds containing aluminium include, for example, aluminium salts, specifically including, for example, aluminum hydroxide and aluminum chloride.

[0009] Among these inorganic compounds, preferred are inorganic compounds containing silica and inorganic compounds containing aluminium; and more preferred are inorganic compounds containing silica. As the inorganic compounds containing silica, preferred is silicic acid anhydride; and more preferred is light anhydrous silicic acid.

50 [0010] The organic compound includes, for example, sugars, amino acids, protein, nucleic acid, and organic acids. The sugars include, for example, polysaccharides such as starch, cellulose, chitin and chitosan; oligosaccharides such as lactose and sucrose; monosaccharides such as mannitol and glucose. As the cellulose, preferred is crystal cellulose. The amino acids include naturally occurring α -amino acids such as glycine, glutamic acid, glutamine, lysine, aspartic acid, and asparagine. The protein includes, for example, globulin and albumin. The nucleic acid includes, for example, inosinic acid, adenylic acid, thymidinic acid, guanylic acid and cytidylic acid. The organic acids include, for example,
 55 lactic acid, acetic acid and citric acid. As the organic compound, preferred are sugars such as mannitol, lactose and crystal cellulose.

[0011] One example of the tablet of the present invention comprises the isotope-labeled urea and such inorganic compound. The content of the isotope-labeled urea is 2 to 2,000 mg, preferably 20 to 350 mg per one tablet. The content of the inorganic compound is 0.1 to 200 parts by weight, preferably 0.5 to 100 parts by weight, and more preferably 1 to 50 parts by weight based on 100 parts by weight of the isotope-labeled urea.

5 [0012] The tablet of the present invention may optionally contain the organic compound. More preferably, the tablet contains the isotope-labeled urea, the inorganic compound and the organic compound. The content of the organic compound is 0 to 1000 parts by weight, preferably 10 to 500 parts by weight, and more preferably 100 to 300 parts by weight based on 100 parts by weight of the isotope-labeled urea in the tablet.

10 [0013] The tablet of the present invention may optionally contain a disintegrant. In respect of the shortened disintegration time after the administration of the tablet, it is preferable that the tablet contains the isotope-labeled urea, the inorganic compound and the disintegrant or that the tablet contains the isotope-labeled urea, the inorganic compound, the organic compound and the disintegrant. The disintegration time of the tablet containing the disintegrant can be adjusted, depending on the amount of the disintegrant to be added. The disintegration time of the tablet of the present invention in stomach is 5 seconds to 10 minutes, preferably 10 seconds to 2 minutes, and particularly preferably 15

15 seconds to 60 seconds. The disintegration time can be measured according to the Disintegration Test of the Japanese Pharmacopoeia.
[0014] Any disintegrant for use in formulation may be used, with no specific limitation, including, for example, polyplasdone, flow-substituted hydroxypropyl cellulose, croscarmellose sodium, carboxymethyl cellulose and the calcium salt thereof, hydroxypropyl starch and the like; preferred examples are polyplasdone and low-substituted hydroxypropyl

20 cellulose.
[0015] The content of the disintegrant is 0 to 500 parts by weight, preferably 1 to 100 parts by weight and more preferably 3 to 20 parts by weight based on 100 parts by weight of the isotope-labeled urea in the tablet.

[0016] Additionally, the tablet of the present invention may optionally contain other additives frequently used for the formulation of other tablets, such as, lubricants, coloring agents, sweetening agents, antioxidants and binders.

25 [0017] The lubricants include for example magnesium stearate, calcium stearate, zinc stearate, stearic acid, talc, hydrogenated vegetable oil, and talc.

[0018] Example of the coloring agents include yellow ferric oxide, iron sesquioxide, various edible dyes, and sodium copper chlorophyllin.

30 [0019] Example of the sweetening agents include sucrose, saccharin, aspartame, mannitol, dextran, lemon flavor, menthol, and citric acid.

[0020] Example of the antioxidants include ascorbic acid and reduced-type glutathione.

[0021] Example of the binders include polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, starch, dextrin, α -type starch, pullulan, gum arabic, agar, gelatin, and purified sugar; preferred is hydroxypropyl cellulose.

35 [0022] By firstly preparing a tablet of a lens shape (of a diameter of 6.5 mm ϕ) by a rotary tableting machine (Correct 12HUK, manufactured by Kikusui Seisakusho) and subjecting the tablet to a disintegration test in the test solution No. (artificial gastrointestinal fluid, pH 1.2) according to the Disintegration Test of the Japanese Pharmacopoeia, the hardness of the tablet of a disintegration time of 120 seconds is measured by a tablet break strength tester (TH-203CP, manufactured by Toyama Industry). The tablet of the present invention has hardness of preferably 5 kgf or more, more preferably 10 kgf. If the disintegration time of the tablet is 60 seconds, the tablet is of hardness of preferably 4 kgf or more, more preferably 8 kgf or more. If the disintegration time of the tablet is 30 seconds, the tablet is of hardness of preferably 3 kgf or more, more preferably 6 kgf or more.

[0023] The method for producing the tablet of the present invention is described below.

45 [0024] Tablet of the present invention, which is characterized in that the stickiness of urea can be prevented, is produced by mixing the urea with the inorganic compound and, if necessary, the organic compound, and if necessary, grinding the resulting mixture. The mixing may be carried out by routine mixing procedures, by a mixer for example V-type blender. The grinding is also carried out by routine grinding procedures by means of grinders, for example sample mill grinder.

50 [0025] The average particle size of the ground product is preferably 100 μ m or less, particularly preferably 50 μ m or less.

[0026] By mixing the urea with the inorganic compound and if necessary, the organic compound, and, if necessary, grinding the resulting mixture, the mixture or the ground mixture can be formulated into a tablet by routine industrial tableting process with no use of any specific tableting process. More specifically, by mixing the urea with the inorganic compound, the cohesion potency of the urea and the stickiness due to the potency onto formulation machines such

55 as tableting machine can be prevented, resulting in the improvement of the industrial productivity.
[0027] The tablet can be produced by mixing the isotope-labeled urea with the inorganic compound and, if necessary, additives including the organic compound, the disintegrant and the lubricants, in a mixer, and, if necessary, grinding the resulting mixture by means of grinder to directly tablet the resulting mixture in powder or the ground mixture by a

tableting machine and the like or press the mixture by a hydraulic pressing machine. Preferably, the tablet containing the organic compound or the disintegrant may be prepared, by preliminarily mixing them with a binder by dry or wet process and, if necessary, grinding the mixture, and subsequently tableting the mixture. For example, the tablet can be produced by mixing the isotope-labeled urea, the inorganic compound and the organic compound or the disintegrant together in a mixer and, if necessary, grinding the resulting mixture, then adding a binder in aqueous solution or ethanol solution for granulation, drying, and if necessary, adding a lubricant and the like thereto. The concentration of the binder in ethanol solution is preferably 20 w/w % or less.

[0028] The resulting tablet may be coated with various coatings and sugar coatings, if necessary.

[0029] In order to diagnose the infection with *Helicobacter pylori* using the tablet of the present invention, isotope-labeled substance, which is discharged, as a metabolite, from the orally administered tablet of the present invention into, for example, expired air, is determined. Generally, $^{13}\text{CO}_2$ or $^{14}\text{CO}_2$ in expired air is measured by an infrared analyzer or a mass analyzer. In case that the isotope-labeled substance is radioactive such as $^{14}\text{CO}_2$, radiation counter may be used.

[0030] The effect of the present invention are now described in the following test examples.

Test Example 1

[0031] Together with the compounds shown in Table 1, urea was ground and mixed in a mortar. After the process, the presence or absence of urea cohesion was observed. The results are shown in Table 1.

Table 1

Compound	Weight ratio to urea	Cohesion
Non	—	observed
Crystal cellulose	1.0	not observed
Light anhydrous silicic acid	1.0	not observed
Light anhydrous silicic acid	0.5	not observed
Light anhydrous silicic acid	0.1	not observed
Calcium carbonate	1.0	not observed
Magnesium aluminate hydrogen phosphate	1.0	not observed
Aluminium hydroxide	1.0	not observed

[0032] By mixing these organic compounds or inorganic compounds with urea, the urea cohesion due to the stickiness of urea can be prevented.

Test Example 2

[0033] As shown in Table 2, 100 g of urea was mixed with various inorganic compounds or organic compounds, and the resulting mixture was ground in a grinder (Sample Mill Grinder of Type KEWG-1F, manufactured by Fuji Paudal). The extent of cohesion was observed subsequently. The results are shown in Table 2.

Table 2

Composition (g)				Assessment
urea	mannitol	crystal cellulose	light anhydrous silicic acid	
100	—	—	—	×
100	300	—	—	○
100	—	100	—	○
100	—	150	—	⊙
100	—	—	5	○
100	—	—	8	⊙

EP 0 860 170 B1

Table 2 (continued)

Composition (g)				Assessment
urea	mannitol	crystal cellulose	light anhydrous silicic acid	
100	—	—	10	⊙
100	—	50	3	○
100	—	100	3	⊙
× : strong cohesion of powder solidified after grinding was observed. ○ : slight cohesion of powder after grinding was observed. ⊙ : no cohesion of powder after grinding was observed.				

[0034] Strong cohesion was observed with respect to the resulting ground product of urea alone; the product was at a solidified state such that the product could not be disintegrated even if pushed strongly. However, the product mixed with the inorganic compounds or organic compounds could suppress urea cohesion. If the product of urea alone was ground for a prolonged term, the grinder was overloaded because of sticking of urea. Thus, it is concluded that the stickiness of urea should be prevented for industrially producing tablets containing urea.

Test Example 3

[0035] According to the Disintegration Test of the Japanese Pharmacopoeia, the tablets obtained in Examples 4 to 8 were subjected to a disintegration test in test solution No. 1 (artificial gastric juice, pH 1.2). The hardness of the tablets was measured by a tablet break strength meter (TH-203CP, manufactured by Toyama Industry). The tablet diameter and thickness were measured by a dial gage (SM-528, manufactured by Teclock). The results are shown in Table 3.

Table 3

Item	Example 4	Example 5	Example 6	Example 7	Example 8
Tablet diameter (mm Ø)	8.5	8.5	8.5	8.5	9.0
Tablet thickness (mm)	4.6	4.5	4.6	4.4	5.2
Tablet hardness (kgf)	7.4	4.2	6.5	7.5	8.7
Disintegration time (sec)	40	58	55	22	45

[0036] The resulting tablets had hardness of 4 kgf or more, with the disintegration times within one minute. Thus, the tablets had excellent properties.

[0037] By a hydraulic pressing machine [P-1B, manufactured by Riken Instruments, Co.], the same mixture powders (250 mg) as those in the individual Examples were prepared into tablets by modifying the tableting pressure at 10 kgf, 15 kgf and 20 kgf, to determine the tablet hardness and disintegration time.

Table 4

Tablet compositions	Tablet thickness (mm)	Hardness (kgf)	Disintegration time (sec)
Example 4	3.84	11.6	96
Example 4	3.79	12.3	120
Example 4	3.65	18.5	186
Example 5	3.84	9.6	58
Example 5	3.68	15.6	122
Example 5	3.67	17.8	178
Example 6	4.20	4.3	46
Example 6	4.12	8.3	98
Example 6	4.09	9.1	114

Table 4 (continued)

Tablet compositions	Tablet thickness (mm)	Hardness (kgf)	Disintegration time (sec)
Example 7	4.07	7.1	33
Example 7	3.92	9.3	80
Example 7	3.89	10.2	88
Example 8	3.69	4.3	19
Example 8	3.55	6.0	31
Example 8	3.50	5.9	39

[0038] These data were statistically treated. If the disintegration time of each tablet is preset at 30 seconds, the tablets of Examples 4, 5, 6, 7 and 8 can procure individually hardness values of 5.5 kgf, 7.8 kgf, 3.2 kgf, 6.9 kgf and 5.4 kgf, respectively. Hence, it is expected that very hard tablets can be produced. If the disintegration time of each tablet is preset at 60 seconds, the tablets of Examples 4, 5, 6, 7 and 8 can procure individually hardness values of 8.0 kgf, 10.0 kgf, 5.3 kgf, 8.5 kgf and 8.6 kgf, respectively. Hence, it is also expected that very hard tablets can be produced. If the disintegration time of each tablet is preset at 120 seconds, the tablets of Examples 4, 5, 6, 7 and 8 can procure individually hardness values of 13.0 kgf, 14.4 kgf, 9.7 kgf, 11.7 kgf and 15.0 kgf, respectively. Hence, it is expected that very hard tablets can be produced.

Test Example 4

[0039] The tablet obtained in Example 7 and a control aqueous solution of the mixture having the same composition [^{13}C -urea (75 mg), crystal cellulose (75 mg), light anhydrous silicic acid (2.5 mg), D-mannitol (81.25 mg), polyplasdone (12.5 mg), hydroxypropyl cellulose (2.5 mg) and magnesium stearate (1.25 mg)] were administered to human subjects. The subjects were preliminarily examined by biopsy under an endoscope, as to whether each subject was positive or negative of *Helicobacter pylori*. The tablet was administered together with water of the same volume as the volume of the aforementioned aqueous solution. Immediately after administration, $^{13}\text{CO}_2$ in expired air was measured over time. $^{13}\text{CO}_2$ in expired air was measured by a mass analyzer specific for $^{13}\text{CO}_2$ -urea breath test [VG Isochrom- μG , Fisons Instruments. Co.]. The results are shown in Table 5.

Table 5

Formulation of diagnostic agents	Infection	Time after administration (min)								
		0	5	10	15	20	25	30	45	60
Aqueous solution	not infected	0	9.5	3.5	1.5	—	—	0.5	0.5	0.5
Aqueous solution	infected	0	15.0	14.5	12.0	13.5	11.0	12.8	11.3	10.8
Tablet	not infected	0	1.0	0.5	0.9	0.1	1.6	1.8	1.0	1.9
Tablet	infected	0	6.0	10.5	11.0	12.5	13.0	13.8	14.3	13.8

[0040] The figures in the table represent the content of $^{13}\text{CO}_2$ (%) in the whole carbon dioxide in expired air. As apparently shown by the change of the content of $^{13}\text{CO}_2$ in the expired air over time in Table 5, it is observed that the content of $^{13}\text{CO}_2$ in the expired air from the subjects positive and negative with *Helicobacter pylori* infection after administration of the aqueous solution of $^{13}\text{CO}_2$ -urea was initially elevated at an early stage of 5 to 10 minutes, but the content in the expired air from the subjects negative with *Helicobacter pylori* infection after administration of the tablet of $^{13}\text{CO}_2$ -urea was not initially elevated. Accordingly, the influences of oral bacterial-flora on the tablet of $^{13}\text{CO}_2$ -urea can be suppressed so that accurate and rapid diagnosis of the infection can be practiced.

Test Example 5

[0041] The tablets produced in Examples 9 and 10 and Reference Example 1 were measured by the same method as in the Test Example 3. The results are shown in Table 6.

Table 6

Tablet composition	Tableting pressure (kgf)	Tablet diameter (mm Ø)	Tablet thickness (mm)	Hardness (kgf)	Disintegration time (sec)
Example 9	10	8.0	3.3	22.2	82
Example 9	15	8.0	3.0	31.1	93
Example 9	20	8.0	2.9	32.2	166
Example 10	10	8.0	3.0	20.0	222
Example 10	15	8.0	3.0	23.5	341
Example 10	20	8.0	2.9	26.6	358
Reference Example 1	10	8.1	3.0	6.8	246
Reference Example 1	15	8.1	3.0	7.0	299
Reference Example 1	20	8.1	2.9	7.7	310

[0042] These data were statistically treated. If the disintegration time of each tablet is preset at 30 seconds, the tablets of Examples 9 and 10 can procure individually hardness values of 13.6 kgf and 10.1 kgf, respectively, which indicates that the tablets are of larger hardness, but the tablet of Reference Example 1 has hardness of 2.7 kgf, which indicates that the tablet is soft. If the disintegration time of each tablet is preset at 60 seconds, the tablets of Examples 9 and 10 can procure individually hardness values of 19.0 kgf and 11.6 kgf, respectively, which indicate that the tablets are of larger hardness, but the tablet of Reference Example 1 has hardness of 3.2 kgf, which indicates that the tablet is soft. If the disintegration time of each tablet is preset at 120 seconds, the tablets of Examples 9 and 10 can procure individually hardness values of 29.6 kgf and 14.4 kgf, respectively, which indicates that the tablets are of larger hardness, but the tablet of Reference Example 1 has hardness of 4.3 kgf, which indicates that the tablet is soft.

Test Example 6

[0043] The tablets produced in Examples 11 and 12 and Reference Example 2 were measured by the same method as in the Test Example 3. The results are shown in Table 7.

Table 7

Tablet composition	Tablet thickness (mm)	Hardness (kgf)	Disintegration time (sec)
Example 11	3.35	21.2	238
Example 11	3.40	16.8	223
Example 11	3.45	15.0	122
Example 11	3.50	12.9	42
Example 12	3.35	17.5	679
Example 12	3.40	13.9	635
Example 12	3.45	12.4	348
Example 12	3.50	10.7	121
Reference Example 2	3.25	3.0	210
Reference Example 2	3.30	3.1	208
Reference Example 2	3.35	2.9	187

[0044] These data were statistically treated. If the disintegration time of each tablet is preset at 30 seconds, the tablets of Examples 11 and 12 can procure individually hardness values of 11.0 kgf and 8.5 kgf, respectively, which

EP 0 860 170 B1

indicates that the tablets are of larger hardness, but the tablet of Reference Example 2 has hardness of 1.4 kgf, which indicates that the tablet is soft. If the disintegration time of each tablet is preset at 60 seconds, the tablets of Examples 11 and 12 can procure individually hardness values of 12.3 kgf and 8.8 kgf, respectively, which indicates that the tablets are of larger hardness, but the tablet of Reference Example 2 has hardness of 1.7 kgf, which indicates that the tablet is soft. If the disintegration time of each tablet is preset at 120 seconds, the tablets of Examples 11 and 12 can procure individually hardness values of 14.9 kgf and 9.6 kgf, respectively, which indicates that the tablets are of larger hardness, but the tablet of Reference Example 2 has hardness of 2.2 kgf, which indicates that the tablet is soft.

Reference Example 1

[0045] ¹³C-urea (50 g), crystal cellulose (60 g), citric acid anhydride (63 g), croscarmellose sodium (24 g) and magnesium stearate (3 g) were mixed together, and the resulting mixture was then ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter of 100 μm or less. Then, 200 mg of the mixture powder was pressed at individual pressures of 10, 15 and 20 kgf, by means of a hydraulic pressing machine [P-1B, manufactured by Riken Instruments, Co.] to prepare tablets.

Reference Example 2

[0046] ¹³C-urea (500 g), crystal cellulose (600 g), citric acid anhydride (630 g), croscarmellose sodium (240 g) and magnesium stearate (30 g) were charged in a V-type blender for mixing therein for 5 minutes, and the resulting mixture was then ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter of 100 μm or less, followed by tableting by a rotary tableting machine (Correct 12HUK, manufactured by Kikusui Seisakusho) by means of a mold of 8.5 mm, to prepare a tablet of 200 mg. If the mixture was left to stand without tableting process, the urea was observed to aggregate together. During the process of tableting, a slight degree of sticking was also observed.

Examples

[0047] Examples will be described below.

Example 1

[0048] ¹³C-urea (1100 g) and light anhydrous silicic acid (100 g) were mixed together, and the resulting mixture was ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter to 100 μm or less. Then, 300 mg of the mixture powder was pressed by a hydraulic pressing machine (P-1B, manufactured by Riken Instruments, Co.) to produce a tablet of 300 mg (containing 275 mg of ¹³C-urea).

Example 2

[0049] ¹³C-urea (1000 g) and light anhydrous silicic acid (200 g) were mixed together, and the resulting mixture was ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter to 100 μm or less. Then, 300 mg of the mixture powder was pressed by a hydraulic pressing machine (P-1B, manufactured by Riken Instruments, Co.) to produce a tablet of 300 mg (containing 250 mg of ¹³C-urea).

Example 3

[0050] ¹³C-urea (1000 g), crystal cellulose (900 g) and light anhydrous silicic acid (100 g) were mixed together, and the resulting mixture was ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter to 100 μm or less. Then, 300 mg of the mixture powder was pressed by a hydraulic pressing machine (P-1B, manufactured by Riken Instruments, Co.) to produce a tablet of 300 mg (containing 150 mg of ¹³C-urea).

Example 4

[0051] ¹³C-urea (1000 g), crystal cellulose (1000 g) and light anhydrous silicic acid (30 g) were charged in a V-type blender (Type VI-20, manufactured by Tokujin Kosakusho) for mixing therein for 5 minutes, and the resulting mixture was then ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter of 100 μm or less. The ground product was charged into a high-speed agitation tableting machine

(Type FM-VG-25P, manufactured by Fuji Industry, Co.), followed by addition of corn starch (307.5 g) and polyplasdon (125 g) and subsequent injection of a 5 w/w % hydroxypropyl cellulose solution in ethanol (500 g) for granulation. The resulting granule product was dried by using a fluidized-bed granulation dryer (Type WSG-5, manufactured by Glatt Co.) at an inlet air temperature of 60 °C for 30 minutes. The dried powder was prepared as a uniform granule through a metal net of No.24, followed by addition of magnesium stearate (12.5 g), for mixing by means of a V-type blender for 3 minutes. The mixture powder was tableted by means of a rotary tableting machine (Correct 12HUK, manufactured by Kikusui Seisakusho) with a metal mold of 8.5 mm, to prepare a tablet of 250 mg (containing 100 mg of ¹³C-urea).

Example 5

[0052] ¹³C-urea (1000 g) and light anhydrous silicic acid (80 g) were charged in a V-type blender (Type VI-5, manufactured by Tokuju Kosakusho), for mixing therein for 5 minutes, and the resulting mixture was then ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KWG-1F) to a final average particle diameter of 100 μm or less. The ground product was charged into a high-speed agitation tableting machine (Type FM-VG-25P, manufactured by Fuji Industry, Co.), followed by addition of lactose (835 g), crystal cellulose (535 g) and hydroxypropyl cellulose (25 g) and subsequent injection of ethanol (500 g) for granulation. The resulting granule product was dried by using a fluidized-bed granulation dryer (Type WSG-5, manufactured by Glatt, Co.) at an inlet air temperature of 60 °C for 30 minutes. The dried powder was prepared as a uniform granule through a metal net of No.24, followed by addition of magnesium stearate (25 g) and mixing by means of a V-type blender (Type VI-20, manufactured by Tokuju Kosakusho) for 3 minutes. The mixture powder was tableted by means of a rotary tableting machine (Correct 12HUK, manufactured by Kikusui Seisakusho) with a metal mold of 8.5 mm, to prepare a tablet of 250 mg (corresponding to 100 mg of ¹³C-urea).

Example 6

[0053] The powder mixed and ground in the same manner as in Example 4 (2030 g), corn starch (307.5 g) and polyplasdone (125 g) were charged in a fluidized-bed granulation dryer (Type WSG-5, manufactured by Glatt, Co.), followed by spraying of an aqueous 5 w/w % hydroxypropyl cellulose solution, to prepare granule products by routine methods. The granule products were prepared as a uniform granule through a metal net of No.24, followed by addition of magnesium stearate (12.5 g), for mixing by means of a V-type blender (Type VI-20, manufactured by Tokuju Kosakusho) for 3 minutes. The mixture powder was tableted by means of a rotary tableting machine (Correct 12HUK, manufactured by Kikusui Seisakusho) with a metal mold of 8.5 mm, to prepare a tablet of 250 mg (containing 100 mg of ¹³C-urea).

Example 7

[0054] ¹³C-urea (750 g), crystal cellulose (750 g) and light anhydrous silicic acid (25 g) were charged in a V-type blender (Type VI-20, manufactured by Tokuju Kosakusho) for mixing therein for 5 minutes, and the resulting mixture was then ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KWG-1F) to a final average particle diameter of 100 μm or less. The ground product was charged into a high-speed agitation tableting machine (Type FM-VG-25P, manufactured by Fuji Industry, Co.), followed by addition of D-mannitol (812.5 g) and polyplasdone (125 g) and subsequent injection of a 5 w/w % hydroxypropyl cellulose in ethanol (500 g) for granulation. The resulting granule product was dried by using a fluidized-bed granulation dryer (Type WSG-5, manufactured by Glatt, Co.) at an inlet air temperature of 60 °C for 30 minutes. The dried powder was prepared as a uniform granule through a metal net of No.24, followed by addition of magnesium stearate (12.5 g) and mixing by means of a V-type blender for 3 minutes. The mixture powder was tableted by means of a rotary tableting machine (Correct 12HUK, manufactured by Kikusui Seisakusho) with a metal mold of 8.5 mm, to prepare a tablet of 250 mg (corresponding to 75 mg of ¹³C-urea).

Example 8

[0055] ¹³C-urea (1000 g) and aluminum hydroxide (1000 g) were charged in a V-type blender for mixing therein for 5 minutes, and the resulting mixture was then ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KWG-1F) to a final average particle diameter of 100 μm or less. The ground product was charged into a high-speed agitation tableting machine, followed by addition of crystal cellulose (805 g) and polyplasdone (150 g) and subsequent injection of a 5 w/w % hydroxypropyl cellulose in ethanol (600 g) for granulation. The resulting granule product was dried by using a fluidized-bed granulation dryer at an inlet air temperature of 60 °C for 30 minutes. The dried powder was prepared as a uniform granule through a metal net of No.24, followed by addition of magnesium stearate (15 g) and mixing by means of a V-type blender for 3 minutes. The mixture powder was tableted by means

of a rotary tableting machine with a metal mold of 9 mm, to prepare a tablet of 300 mg (containing 100 mg of ^{13}C -urea).

Example 9

- 5 [0056] ^{13}C -urea (167 mg) and light anhydrous silicic acid (33 g) were mixed together, and the resulting mixture was ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter to 100 μm or less. Then, 200 mg of the mixture powder was pressed by a hydraulic pressing machine (P-1B, manufactured by Riken Instruments, Co.) at individual tableting pressures of 10, 15 and 20 kgf to produce tablets.

10 Example 10

- [0057] ^{13}C -urea (100 g), crystal cellulose (90 g) and light anhydrous silicic acid (10 g) were mixed together, and the resulting mixture was ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter to 100 μm or less. Then, 200 mg of the mixture powder was pressed by a hydraulic pressing machine (P-1B, manufactured by Riken Instruments, Co.) at tableting pressures of 10, 15 and 20 kgf, to produce tablets.

Example 11

- 20 [0058] ^{13}C -urea (1000 g) and light anhydrous silicic acid (200 g) were charged in a V-type blender for mixing for 5 minutes. The resulting mixture was ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter to 100 μm or less, followed by tableting by a rotary-type tableting machine (Correct 12HUK, manufactured by Kikusui Seisakusho) with a mold of 8.5 mm, to produce a tablet of 200 mg.

25 Example 12

- [0059] ^{13}C -urea (1000 g), crystal cellulose (900 g) and light anhydrous silicic acid (100 g) were charged in a V-type blender for mixing for 5 minutes. The resulting mixture was ground by a grinder (Sample Mill Grinder, manufactured by Fuji Paudal, Type KEWG-1F) to a final average particle diameter to 100 μm or less, followed by tableting by a rotary-type tableting machine (Correct 12HUK, manufactured by Kikusui Seisakusho) with a mold of 8.5 mm, to produce a tablet of 200 mg.

Industrial Applicability

- 35 [0060] The tablet of the isotope-labeled urea of the present invention is useful as a diagnostic agent for detecting the infection with urease-producing bacteria, specifically *Helicobacter pylori*. By the method of the present invention, the stickiness of urea can be prevented, so such urea can be formulated into tablets at an industrial scale. The tablet of the present invention has such appropriate hardness that the tablet is hardly worn or broken through the impact during the production or delivery or the tablet is less influenced by urease derived from oral bacterial flora.

Claims

1. A tablet containing isotope-labeled urea and an inorganic compound.
2. A tablet according to claim 1, further containing an organic compound.
3. A tablet according to claim 1, further containing a disintegrant.
4. A tablet according to claim 1, further containing an organic compound and a disintegrant.
5. A tablet according to any one of claims 1 to 4, wherein the inorganic compound is selected from the group consisting of inorganic compounds containing silica and inorganic compounds containing aluminium.
6. A tablet according to claim 2 or 4, wherein the organic compound is a sugar.
7. A tablet according to claim 3 or 4, wherein the disintegrant is selected from the group consisting of polyplasdone, low-substituted hydroxypropyl cellulose, croscarmellose sodium, carboxymethyl cellulose or the calcium salt there-

of, and hydroxypropyl starch.

Patentansprüche

5

1. Tablette, enthaltend Isotopen-markierten Harnstoff und eine anorganische Verbindung.
2. Tablette nach Anspruch 1, enthaltend ferner eine organische Verbindung.
- 10 3. Tablette nach Anspruch 1, enthaltend ferner ein Sprengmittel.
4. Tablette nach Anspruch 1, enthaltend ferner eine organische Verbindung und ein Sprengmittel.
5. Tablette nach einem der Ansprüche 1 bis 4, wobei die anorganische Verbindung aus anorganischen Verbindungen, enthaltend Siliciumdioxid, und anorganischen Verbindungen, enthaltend Aluminium, ausgewählt ist.
- 15 6. Tablette nach Anspruch 2 oder 4, wobei die organische Verbindung ein Zucker ist.
7. Tablette nach Anspruch 3 oder 4, wobei das Sprengmittel aus Polyplasdon, nieder substituierter Hydroxypropyl-cellulose, Natriumcrosscarmellose, Carboxymethylcellulose oder dem Calciumsalz davon und Hydroxypropylstärke ausgewählt ist.
- 20

Revendications

25

1. Comprimé contenant un composé inorganique et de l'urée marquée par un isotope.
2. Comprimé conforme à la revendication 1, qui contient en outre un composé organique.
- 30 3. Comprimé conforme à la revendication 1, qui contient en outre un désintégrant.
4. Comprimé conforme à la revendication 1, qui contient en outre un composé organique et un désintégrant.
5. Comprimé conforme à l'une des revendications 1 à 4, dans lequel le composé inorganique est choisi dans l'ensemble constitué par les composés inorganiques contenant de la silice et les composés inorganiques contenant de l'aluminium.
- 35 6. Comprimé conforme à la revendication 2 ou 4, dans lequel le composé organique est un sucre.
7. Comprimé conforme à la revendication 3 ou 4, dans lequel le désintégrant est choisi dans l'ensemble constitué par la polyplasdone, l'hydroxypropylcellulose à faible taux de substitution, le sel sodique de carboxyméthylcellulose réticulée, la carboxyméthylcellulose, le sel calcique de cette dernière, et l'hydroxypropylamidon.
- 40

45

50

55